# Novel Therapeutic Hypotheses for Age-Related Neurodegeneration
## 1. Senescence-Activated NAD+ Depletion Rescue
**Description:** Senescent glial cells upregulate CD38 NADase, creating local NAD+ depletion zones that impair neuronal energy metabolism and synaptic function. Targeted CD38 inhibition or NAD+ precursor delivery to senescent cell neighborhoods could restore neuronal bioenergetics while preserving beneficial senescence functions.
**Target:** CD38 NADase/NAMPT pathway
**Supporting Evidence:** CD38 is highly expressed in senescent cells and correlates with NAD+ decline in aging brains (PMID: 32669541). NAD+ depletion precedes neuronal dysfunction in Alzheimer's models (PMID: 30674985).
**Confidence:** 0.75
## 2. SASP-Mediated Complement Cascade Amplification
**Description:** Senescent astrocytes secrete C1q and other complement initiators, creating localized complement activation that tags healthy synapses for microglial elimination. Selective C1q or C3 inhibition in senescent cell microenvironments could prevent pathological synapse loss while maintaining immune surveillance.
**Target:** C1Q/C3 complement proteins
**Supporting Evidence:** SASP includes complement factors (PMID: 28065329), and complement-mediated synapse elimination drives cognitive decline (PMID: 26814963). C1q knockout protects against age-related synapse loss (PMID: 23328393).
**Confidence:** 0.82
## 3. Senescence-Induced Lipid Peroxidation Spreading
**Description:** p16+ senescent cells exhibit dysregulated iron homeostasis and reduced antioxidant capacity, generating lipid peroxidation products (4-HNE, MDA) that propagate oxidative damage to neighboring neurons through gap junctions and extracellular vesicles. Targeted delivery of lipophilic antioxidants or iron chelators to senescent cells could break this propagation chain.
**Target:** Ferroptosis pathway (GPX4, SLC7A11)
**Supporting Evidence:** Senescent cells show increased iron accumulation and lipid peroxidation (PMID: 31398223). Ferroptosis contributes to neurodegeneration (PMID: 33037393), and SASP vesicles transfer oxidative damage (PMID: 30683798).
**Confidence:** 0.68
## 4. Senescent Cell Mitochondrial DNA Release
**Description:** Senescent glial cells release damaged mitochondrial DNA through compromised mitophagy and nuclear envelope breakdown, activating cGAS-STING innate immunity in surrounding neurons. This creates a feed-forward inflammatory loop. DNase II delivery or STING inhibition specifically in neural tissues could interrupt this cascade.
**Target:** cGAS-STING pathway/DNase II
**Supporting Evidence:** Senescent cells release mtDNA activating cGAS-STING (PMID: 29212815). Neuronal STING activation drives neurodegeneration (PMID: 34610202), and mtDNA accumulates in aging brains (PMID: 28877457).
**Confidence:** 0.71
## 5. SASP-Driven Aquaporin-4 Dysregulation
**Description:** Senescent astrocytes secrete TNF-α and IL-1β that downregulate AQP4 water channels in neighboring healthy astrocytes, impairing glymphatic clearance and allowing toxic protein accumulation. Restoring AQP4 function through targeted gene therapy or small molecule enhancers could restore brain waste clearance despite senescent cell presence.
**Target:** AQP4 aquaporin channels
**Supporting Evidence:** TNF-α reduces AQP4 expression (PMID: 25159663), glymphatic dysfunction accelerates neurodegeneration (PMID: 32669985), and SASP cytokines impair astrocytic functions (PMID: 33846038).
**Confidence:** 0.77
## 6. Senescence-Associated Myelin Lipid Remodeling
**Description:** p21+ senescent oligodendrocytes alter myelin lipid composition by upregulating phospholipase A2, creating myelin with increased membrane fluidity that impairs action potential propagation and makes axons vulnerable to degeneration. Targeted PLA2 inhibition or lipid supplementation could stabilize myelin integrity.
**Target:** Phospholipase A2 (PLA2G6/PLA2G4A)
**Supporting Evidence:** Senescent cells show altered lipid metabolism (PMID: 31831667), PLA2 mutations cause neurodegeneration (PMID: 29127354), and myelin lipid changes occur in aging (PMID: 33758796).
**Confidence:** 0.62
## 7. SASP-Mediated Cholinergic Synapse Disruption
**Description:** Senescent microglia secrete matrix metalloproteinases that cleave perineuronal nets around cholinergic neurons, disrupting acetylcholine release and cognitive function. This occurs independently of direct neuronal damage. Selective MMP inhibition or perineuronal net components replacement could restore cholinergic function without requiring senescent cell elimination.
**Target:** Matrix metalloproteinases (MMP2/MMP9)
**Supporting Evidence:** SASP includes elevated MMPs (PMID: 25455326), perineuronal net degradation impairs cognition (PMID: 24759575), and cholinergic dysfunction is early in neurodegeneration (PMID: 30914030).
**Confidence:** 0.73